DSM-5 attenuated 精神病综合征的临床效度:诊断、预后与治疗进展
该系统综述纳入56篇文章、124项效度指标,并定量荟萃23项前瞻性队列研究共2376人。DSM-5-APS在临床样本中与抑郁共病、痛苦、自杀倾向及功能损害相关,精神病发作累积风险6个月为11%、12个月为15%、24个月为20%、36个月为23%。易感/促发因素、神经生物学相关因素及有效治疗尚待确定。
要点
- DSM-5-APS与频繁的抑郁共病、痛苦、自杀倾向和功能损害相关。
- 荟萃分析显示精神病发作风险6个月11%、12个月15%、24个月20%、36个月23%。
- 易感/促发因素、神经生物学相关因素及有效治疗尚未确定。
核心结论
- DSM-5-APS标准已获得实质性的同期效度和预后效度验证,主要来自精神病临床高危状态研究。
- 易感/促发因素、神经生物学相关因素及有效治疗迄今尚未确定。
研究设计与样本
- 系统综述遵循PRISMA和MOOSE指南及PROSPERO方案,检索Web of Science、Cochrane Central Register of Reviews、Ovid/PsychINFO、会议录和试验注册库至2019年6月16日。
- 纳入报告原创数据、研究使用DSM-5-APS或符合可比标准诊断个体的研究。
- 系统综述纳入56篇文章,报告124项效度指标,包括15项前因效度、55项同期效度和54项预后效度指标。
- 定量荟萃分析纳入23项前瞻性队列研究,共2376人,探索6、12、24和36个月精神病发作累积风险。
主要发现
- 一般非求助年轻人群中符合DSM-5-APS标准的流行病学患病率为0.3%;临床样本中符合DSM-5-APS标准的个体患病率可变。
- DSM-5-APS标准的评定者间信度与其他DSM-5精神障碍相当,可通过使用特定心理测量工具优化。
- DSM-5-APS标准与频繁的抑郁共病、痛苦、自杀倾向和功能损害相关。
- 荟萃分析显示精神病发作风险6个月为11%、12个月为15%、24个月为20%、36个月为23%。
- 针对DSM-5-APS标准的易感/促发流行病学因素、神经生物学相关因素和有效治疗的研究有限。
关键数值与推荐
- 一般非求助年轻人群中符合DSM-5-APS标准的流行病学患病率为0.3%。
- 荟萃分析(23项前瞻性队列研究,2376人)精神病发作风险:6个月11%、12个月15%、24个月20%、36个月23%。
临床怎么用
- 临床可依据DSM-5-APS标准识别精神病临床高危个体,并关注抑郁共病、痛苦、自杀倾向和功能损害。
- 使用特定心理测量工具可能优化DSM-5-APS标准的评定者间信度。
- 对DSM-5-APS个体应监测精神病发作风险,6至36个月累积风险为11%至23%。
局限性
- 易感/促发因素、神经生物学相关因素及有效治疗的研究有限,迄今尚未确定。
- 临床样本中符合DSM-5-APS标准的个体患病率可变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Since the release of the DSM-5 diagnosis of attenuated psychosis syndrome (DSM-5-APS) in 2013, several research studies have investigated its clinical validity. Although critical and narrative reviews have reviewed these progresses, no systematic review has comprehensively summarized the available evidence regarding the clinical validity of DSM-5-APS. OBJECTIVE: To provide current evidence on the clinical validity of DSM-5-APS, focusing on recent advances in diagnosis, prognosis, and treatment. EVIDENCE REVIEW: A multistep literature search using the Web of Science database, Cochrane Central Register of Reviews, Ovid/PsychINFO, conference proceedings, and trial registries from database inception to June 16, 2019, was conducted following PRISMA and MOOSE guidelines and PROSPERO protocol. Studies with original data investigating individuals diagnosed using DSM-5-APS or meeting comparable criteria were included. The results of the systematic review were summarized in tables and narratively synthesized against established evidence-based antecedent, concurrent, and prognostic validators. A quantitative meta-analysis was conducted to explore the cumulative risk of psychosis onset at 6, 12, 24, and 36 months in individuals diagnosed using DSM-5-APS criteria. FINDINGS: The systematic review included 56 articles, which reported on 124 validators, including 15 antecedent, 55 concurrent, and 54 prognostic validators. The epidemiological prevalence of the general non-help-seeking young population meeting DSM-5-APS criteria was 0.3%; the prevalence of individuals meeting DSM-5-APS criteria was variable in clinical samples. The interrater reliability for DSM-5-APS criteria was comparable with that of other DSM-5 mental disorders and can be optimized by the use of specific psychometric instruments. DSM-5-APS criteria were associated with frequent depressive comorbid disorders, distress, suicidality, and functional impairment. The meta-analysis included 23 prospective cohort studies, including 2376 individuals. The meta-analytical risk of psychosis onset was 11% at 6 months, 15% at 12 months, 20% at 24 months, and 23% at 36 months. Research into predisposing and precipitating epidemiological factors, neurobiological correlates, and effective treatments for DSM-5-APS criteria has been limited. CONCLUSIONS AND RELEVANCE: Over recent years, DSM-5-APS criteria have received substantial concurrent and prognostic validation, mostly driven by research into the clinical high-risk state for psychosis. Precipitating and predisposing factors, neurobiological correlates, and effective treatments are undetermined to date.
引用
- Salazar de Pablo G, Catalan A, Fusar-Poli P, et al. Clinical Validity of DSM-5 Attenuated Psychosis Syndrome: Advances in Diagnosis, Prognosis, and Treatment. JAMA Psychiatry. 2020. PMID: 31746950. doi:10.1001/jamapsychiatry.2019.3561
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。